Ascendis Pharma A (ASND) Long-Term Deferred Tax (2014 - 2026)

Ascendis Pharma A has disclosed Long-Term Deferred Tax across 8 years of filings, most recently posting $808.3 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $808.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $808.3 million (changed N/A YoY), and the FY2025 annual result was -$11.2 million, down 44.43% from the prior year.
• Long-Term Deferred Tax came in at $808.3 million for Q1 2026 at Ascendis Pharma A, up from -$11.2 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $808.3 million in Q1 2026 to a low of -$11.2 million in Q4 2025.
• The 4-year median for Long-Term Deferred Tax is -$7.0 million (2024), against an average of $195.8 million.
• Across the five-year window, Long-Term Deferred Tax fell 23.64% in 2024 and plunged 44.43% in 2025, its largest moves.
• Ascendis Pharma A's Long-Term Deferred Tax stood at -$6.3 million in 2023, then slipped by 23.64% to -$7.8 million in 2024, then sank by 44.43% to -$11.2 million in 2025, then soared by 7315.84% to $808.3 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $808.3 million (Q1 2026), -$11.2 million (Q4 2025), and -$7.8 million (Q4 2024), per Business Quant data.